Liminal Biosciences is a clinical stage biopharmaceutical company focused on developing distinctive small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using Co.'s drug discovery platform and data-driven approach. Co.'s research and development programs are focused on inflammatory, fibrotic and metabolic conditions in patients with respiratory, liver or renal disease. Co.'s pipeline is made up of three development programs. Co.'s main asset, fezagepras (also known as PBI-4050), a clinical-stage product candidate, as a potential nitrogen scavenger and its GPR84 antagonist and OXER1 antagonist programs, which are preclinical.